Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,712,246.04. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Trading Up 0.4%

NASDAQ UTHR opened at $549.87 on Friday. The stock has a 50-day simple moving average of $568.23 and a 200 day simple moving average of $518.83. The company has a market capitalization of $23.34 billion, a PE ratio of 20.30, a P/E/G ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.63 EPS. As a group, sell-side analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent analyst reports. Cantor Fitzgerald upped their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Finally, Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the business. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter worth about $31,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.